These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 22834104)

  • 1. [Essentials of neurocognitive assessment in clinical research].
    Sumiyoshi T
    Nihon Shinkei Seishin Yakurigaku Zasshi; 2012 Jun; 32(3):149-53. PubMed ID: 22834104
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Interest of a new instrument to assess cognition in schizophrenia: The Brief Assessment of Cognition in Schizophrenia (BACS)].
    Bralet MC; Navarre M; Eskenazi AM; Lucas-Ross M; Falissard B
    Encephale; 2008 Dec; 34(6):557-62. PubMed ID: 19081451
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Approaching a consensus cognitive battery for clinical trials in schizophrenia: the NIMH-MATRICS conference to select cognitive domains and test criteria.
    Green MF; Nuechterlein KH; Gold JM; Barch DM; Cohen J; Essock S; Fenton WS; Frese F; Goldberg TE; Heaton RK; Keefe RS; Kern RS; Kraemer H; Stover E; Weinberger DR; Zalcman S; Marder SR
    Biol Psychiatry; 2004 Sep; 56(5):301-7. PubMed ID: 15336511
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comparison of the CogState Schizophrenia Battery and the Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) Battery in assessing cognitive impairment in chronic schizophrenia.
    Pietrzak RH; Olver J; Norman T; Piskulic D; Maruff P; Snyder PJ
    J Clin Exp Neuropsychol; 2009 Oct; 31(7):848-59. PubMed ID: 19142774
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cognitive and psychomotor effects of risperidone in schizophrenia and schizoaffective disorder.
    Houthoofd SA; Morrens M; Sabbe BG
    Clin Ther; 2008 Sep; 30(9):1565-89. PubMed ID: 18840365
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Measuring the cognitive deficit associated with schizophrenia: presentation of the MATRICS neuropsychological test battery].
    Sarolta K; Pál C; István B
    Neuropsychopharmacol Hung; 2007 Oct; 9(3):143-50. PubMed ID: 18399033
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Cognitive deficit in schizophrenia: MATRICS Consensus Cognitive Battery].
    Rodríguez-Jiménez R; Bagney A; Moreno-Ortega M; García-Navarro C; Aparicio AI; López-Antón R; de la Oliva J; Jiménez-Arriero MÁ; Santos JL; Lobo A; Palomo T
    Rev Neurol; 2012 Nov; 55(9):549-55. PubMed ID: 23111994
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A comparative study of the MATRICS and IntegNeuro cognitive assessment batteries.
    Silverstein SM; Jaeger J; Donovan-Lepore AM; Wilkniss SM; Savitz A; Malinovsky I; Hawthorne D; Raines S; Carson S; Marcello S; Zukin SR; Furlong S; Dent G
    J Clin Exp Neuropsychol; 2010 Nov; 32(9):937-52. PubMed ID: 20455131
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Norwegian standardization of the MATRICS (Measurement and Treatment Research to Improve Cognition in Schizophrenia) Consensus Cognitive Battery.
    Mohn C; Sundet K; Rund BR
    J Clin Exp Neuropsychol; 2012; 34(6):667-77. PubMed ID: 22439943
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Cognition, social cognition and functioning in schizophrenia].
    Vaz-Serra A; Palha A; Figueira ML; Bessa-Peixoto A; Brissos S; Casquinha P; Damas-Reis F; Ferreira L; Gago J; Jara J; Relvas J; Marques-Teixeira J
    Acta Med Port; 2010; 23(6):1043-58. PubMed ID: 21627882
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Learning potential and cognitive remediation in schizophrenia].
    Raffard S; Gely-Nargeot MC; Capdevielle D; Bayard S; Boulenger JP
    Encephale; 2009 Sep; 35(4):353-60. PubMed ID: 19748372
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The MATRICS Consensus Cognitive Battery, part 1: test selection, reliability, and validity.
    Nuechterlein KH; Green MF; Kern RS; Baade LE; Barch DM; Cohen JD; Essock S; Fenton WS; Frese FJ; Gold JM; Goldberg T; Heaton RK; Keefe RS; Kraemer H; Mesholam-Gately R; Seidman LJ; Stover E; Weinberger DR; Young AS; Zalcman S; Marder SR
    Am J Psychiatry; 2008 Feb; 165(2):203-13. PubMed ID: 18172019
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Executive function needs to be targeted to improve social functioning with Cognitive Remediation Therapy (CRT) in schizophrenia.
    Penadés R; Catalán R; Puig O; Masana G; Pujol N; Navarro V; Guarch J; Gastó C
    Psychiatry Res; 2010 May; 177(1-2):41-5. PubMed ID: 20381164
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A double-blind study of combination of clozapine with risperidone in patients with schizophrenia: effects on cognition.
    Akdede BB; Anil Yağcioğlu AE; Alptekin K; Turgut TI; Tümüklü M; Yazici MK; Jayathilake K; Tunca Z; Göğüş A; Meltzer HY
    J Clin Psychiatry; 2006 Dec; 67(12):1912-9. PubMed ID: 17194269
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A collaborative approach to targeted treatment development for schizophrenia: a qualitative evaluation of the NIMH-MATRICS project.
    Bromley E
    Schizophr Bull; 2005 Oct; 31(4):954-61. PubMed ID: 16166607
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Frontal dementia or dementia praecox? A case report of a psychotic disorder with a severe decline].
    Vanderzeypen F; Bier JC; Genevrois C; Mendlewicz J; Lotstra F
    Encephale; 2003; 29(2):172-80. PubMed ID: 14567169
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Functional outcome in schizophrenia: relation to the MATRICS consensus cognitive battery].
    Sumiyoshi C
    Nihon Shinkei Seishin Yakurigaku Zasshi; 2011 Nov; 31(5-6):251-7. PubMed ID: 22256615
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Putative cognitive enhancers in preclinical models related to schizophrenia: the search for an elusive target.
    Barak S; Weiner I
    Pharmacol Biochem Behav; 2011 Aug; 99(2):164-89. PubMed ID: 21420999
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neurocognitive function in clinically stable men with bipolar I disorder or schizophrenia and normal control subjects.
    Altshuler LL; Ventura J; van Gorp WG; Green MF; Theberge DC; Mintz J
    Biol Psychiatry; 2004 Oct; 56(8):560-9. PubMed ID: 15476685
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cognitive enhancement therapy for schizophrenia: effects of a 2-year randomized trial on cognition and behavior.
    Hogarty GE; Flesher S; Ulrich R; Carter M; Greenwald D; Pogue-Geile M; Kechavan M; Cooley S; DiBarry AL; Garrett A; Parepally H; Zoretich R
    Arch Gen Psychiatry; 2004 Sep; 61(9):866-76. PubMed ID: 15351765
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.